Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes
Therapeutic alteration of protein expression using modified mRNA is limited by immunogenicity and instability in vivo. Here the authors use antibody-coated lipid nanoparticles to deliver mRNA to leukocytes and drive expression of anti-inflammatory cytokines in an inflammatory bowel disease mouse mod...
Guardado en:
Autores principales: | Nuphar Veiga, Meir Goldsmith, Yasmin Granot, Daniel Rosenblum, Niels Dammes, Ranit Kedmi, Srinivas Ramishetti, Dan Peer |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9f873ddd64ac44b1bc45f41c3236a99a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Progress and challenges towards targeted delivery of cancer therapeutics
por: Daniel Rosenblum, et al.
Publicado: (2018) -
Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes
por: Li-Ming Gan, et al.
Publicado: (2019) -
Transposon-modified antigen-specific T lymphocytes for sustained therapeutic protein delivery in vivo
por: Richard T. O’Neil, et al.
Publicado: (2018) -
Chemically modified mRNA beyond COVID-19: Potential preventive and therapeutic applications for targeting chronic diseases
por: Dana Elkhalifa, et al.
Publicado: (2022) -
Apoptosis- and survival-related gene mRNA profile in peripheral blood leukocytes in children with acute EBV infectious mononucleosis
por: N. A. Sakharnov, et al.
Publicado: (2020)